Busulfan treatment in patients before bone marrow transplantation and early indicators of renal tubular function

Tomasz Burycz¹, Anna Wiela-Hojeńska², Lidia Usnarska-Zubkiewicz³, Krystyna Głowacka², Krystyna Orzechowska-Juzwenko², Kazimierz Kuliczkowski³

¹ Wroclaw Herbal Works „HERBAPOL” Inc., Experimental Laboratory, Ks. Witolda 56, PL 50-203 Wroclaw, Poland
² Department of Clinical Pharmacology, Wroclaw Medical University, Bujwida 44, PL 50-345 Wroclaw, Poland
³ Department of Hematology, Wroclaw Medical University, Pasteura 4, PL 50-367 Wroclaw, Poland

Correspondence: Tomasz Burycz, e-mail tburycz@wroclaw.herbapol.pl

Abstract:
In order to carry out safe anticancer chemotherapy, kidney function should be monitored. The aim of our work was to demonstrate the role of α₁-microglobulin (α₁-M) and N-acetyl-beta-D-glucosaminidase (NAG) for the monitoring of renal function in patients with hematological malignancies before and during high-dose busulfan-based conditioning regimen prior to bone marrow transplantation (BMT). On the basis of our study, we have shown that α₁-M concentrations and NAG activity increased in urine in patients with hematological cancers, especially after 13-dose busulfan therapy. Our preliminary results lead to the conclusion that both supportive therapy and administration of busulfan can impair tubular function. These observations have shown that it is necessary to carry out detail estimation of kidney excretory function during anticancer chemotherapy in the patients waiting for BMT. Detection of an increased α₁-M concentration and NAG activity in urine can be helpful for the recognition of the patients at high risk of tubular dysfunction. Disturbances of kidney function should be considered during the planning of individual drug dosage regimens.

Key words: kidney function, α₁-M, NAG, busulfan

Introduction

Anticancer treatment often has to be limited or is precluded by kidney function disorders related to neoplastic disease or its chemotherapy. Therefore, it is necessary to carry out regular and comprehensive tests of renal function in cancer patients. They could be useful for the rapid medical intervention before the appearance of unwanted clinical symptoms [8, 15].

Because of their properties, a glycoprotein – α₁-microglobulin (α₁-M) and an enzyme – N-acetyl-beta-D-glucosaminidase (NAG) can be used as an early noninvasive indicators of proximal tubular cell damage. Tubular proteinuria occurs when glomerular function is normal, but the proximal tubules have diminished capacity to reabsorb and catabolize proteins, causing an increased urinary excretion of the low molecular weight proteins that normally pass through the
glomerulus, such $\alpha_1$-M. Normal urine contains very small amounts of $\alpha_1$-M. In conditions with disturbed tubular function, kidney transplant rejection, Fanconi syndrome and Balkan nephropathy) and treatment with some drugs (aminoglycosides, cyclosporine), re-absorption of this protein is reduced and its increased amounts are found in urine [2, 18, 20–22, 26, 27, 29]. AG is a lysosomal enzyme located mainly in the renal proximal tubules. Due to its molecular weight (about 150,000), it does not normally pass through the glomerulus. It is physiologically excreted at low amounts in urine. Increased NAG enzymatic activity in urine has been found to be associated with various kidney injuries – arterial hypertension, diabetic nephropathy, renal transplant rejection) and is a sign of drug nephrotoxicity (cisplatinum, ifosfamide) [3, 6, 7, 10, 24]. The increased urinary excretion of these markers often precede clinical signs of renal dysfunction by several days.

The purpose of the present study was to establish the role of $\alpha_1$-M and NAG for the monitoring of renal impairment in patients with hematological malignancies before and during high-dose busulfan-based conditioning regimen prior to bone marrow transplantation.

### Materials and Methods

Studies were carried out in 131 persons: 22 patients before bone marrow transplantation (8 – with chronic myelogenous leukemia (CML), 10 – with acute myeloblastic leukemia (AML), 3 – with acute lymphoblastic leukemia (ALL), 1 – with osteomyelofibrosis) and 65 healthy volunteers as a control group for NAG determination and 44 healthy volunteers as a control group for $\alpha_1$-M determination (Tab. 1).

Renal excretory function ($\alpha_1$-M, creatinine concentrations and NAG activity in urine) was determined before and after 1, 9 and 13 doses of conditioning busulfan therapy. Busulfan was administered orally at a dose of 16 mg/kg b.m. each day for 4 days before BMT. Before and during cytostatic chemotherapy, patients received ciprofloxacin 500 mg × 2 daily doses, trimethoprim/sulfamethoxasole 960 mg × 2 weekly doses, antibiotics according to the result of bacteriological culture (cefotaxim 1000 mg × 3 daily doses, amoxicillin/clavulanic acid 1200 mg × 3 daily doses, ceftazidim 1000 mg × 2 daily doses, meropenem 1000 mg × 3 daily doses, vancomycin 1000 mg × 2 daily doses, imipenem/cilastin 500 mg × 3 daily doses), ketoconazole or fluconazole 200 mg × 2 daily doses and acyclovir 200 mg × 5 daily doses.

$\alpha_1$-M and NAG were analyzed in the second morning spot urine sample. The enzyme-linked immunosorbent assay (ELISA) was used for the quantitative determination of $\alpha_1$-M concentration. Detection limit of the method is 0.006 mg/l, according to the assay kit producer (Immundiagnostik AG). The activity of NAG was determined by the enzymatic method, using p-nitrophenyl-N-acetyl-\(\beta\)-D-glucosamide as a substrate [30]. Released p-nitrophenol (NAG catalyzes the hydrolysis of p-nitrophenyl-N-acetyl-\(\beta\)-D-glucosamide into p-nitrophenol and N-acetylglucosamine), proportional to the enzymatic activity, was determined colorimetrically at 410 nm. Detection limit of the method was 1.6 U/l. The influence of diuresis volume on protein concentration and enzyme activity was eliminated by expressing $\alpha_1$-M concentration and NAG activity in relation to creatinine concentration in urine [3, 4, 14, 18, 24]. Creatinine concentrations in urine were determined according to Jaffe’s colorimetric method.

Statistical comparison between the patient groups was performed with nonparametric Mann-Whitney test. A probability of less than 0.05 was considered statistically significant. The protocol for the study

### Tab. 1. Characteristics of patients and healthy persons as a control group

<table>
<thead>
<tr>
<th>Group</th>
<th>Number of persons</th>
<th>Age (years)</th>
<th>Body weight (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>X ± SD</td>
<td>X ± SD</td>
</tr>
<tr>
<td>Healthy volunteers</td>
<td>65</td>
<td>36.2 ± 8.9</td>
<td>63.2 ± 8.5</td>
</tr>
<tr>
<td>N-acetyl-beta-D-glucosaminidase (NAG)</td>
<td>44</td>
<td>40.1 ± 9.9</td>
<td>68.8 ± 13.8</td>
</tr>
<tr>
<td>$\alpha_1$-microglobulin ($\alpha_1$-M)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients with hematological cancer</td>
<td>22</td>
<td>38.0 ± 11.7</td>
<td>70.6 ± 13.4</td>
</tr>
</tbody>
</table>
was approved by the Ethics Committee of Wroclaw Medical University.

Results

In our study, we observed statistically significant increase in $\alpha_1$-M concentration in a group of patients before and during myeloablative treatment in comparison with the group of healthy volunteers. The mean values of $\alpha_1$-M concentrations in healthy persons, patients before and during conditioning therapy with busulfan are shown in Table 2. Statistically significant differences in the protein concentration between patients before anticancer treatment and healthy persons point to the decrease in kidney tubular function caused by the disease and previous supportive treatment with some drugs (acyclovir, vancomycin, quinolones, cefalosporine derivatives, cotrimoxazole) used before conditioning therapy.

The comparison of the mean values of NAG activity between patient groups before and during busulfan therapy, and healthy volunteers is shown in Table 3.

In the examined groups of patients, the concentration of creatinine in urine differed significantly ($p < 0.05$), regarding the values obtained after the 1st dose of busulfan ($0.84 \pm 0.83$ g/l), 9th ($0.96 \pm 0.61$ g/l), 13th ($0.81 \pm 0.51$ g/l), when compared to this parameter in healthy persons, reaching $1.28 \pm 0.39$ g/l.

Discussion

Kidney diseases frequently complicate malignancy and its treatment. The spectrum of insufficiency of the main organ responsible for drug excretion includes acute or chronic renal failure, and tubular disorders. This problem can be very important in transplant patients.

| Tab. 2. Concentration of $\alpha_1$-microglobulin ($\alpha_1$-M) in patients before and during the conditioning regimen with busulfan and in healthy persons as a control group |
|---|---|---|---|
| Group | Number of persons | $\alpha_1$-M concentration/$\alpha_1$-M/creatinine [mg/g creatinine] | Percent changes in $\alpha_1$-M concentration |
| Healthy volunteers | 44 | 0.74 ± 0.97 |  |
| Patients before busulfan therapy | 17 | 1.04* ± 0.71 | 40.5 |
| Patients after 1st dose of busulfan | 19 | 1.39* ± 0.91 | 87.5 |
| Patients after 9th dose of busulfan | 18 | 2.61* ± 2.60 | 252.7 |
| Patients after 13th dose of busulfan | 17 | 4.00* ± 4.07 | 440.5 |

Statistically significant difference in the mean values of $\alpha_1$-M concentration between healthy volunteers and patients before and during cytostatic treatment:* $p < 0.05$ vs. control group

| Tab. 3. Activity of N-acetyl-beta-D-glucosaminidase (NAG) in patients before and during busulfan chemotherapy and in healthy persons as a control group |
|---|---|---|---|
| Group | Number of persons | NAG activity/NAG/creatinine [U/g creatinine] | Percent changes in NAG activity |
| Healthy volunteers | 65 | 3.52 ± 1.99 |  |
| Patients before busulfan therapy | 18 | 2.86 ± 2.47 | –18.8 |
| Patients after 1st dose of busulfan | 20 | 2.99 ± 1.61 | –15.1 |
| Patients after 9th dose of busulfan | 19 | 3.92 ± 3.04 | 11.4 |
| Patients after 13th dose of busulfan | 18 | 4.88 ± 5.77 | 38.6 |
During our study, we estimated the tubular function in patients with various hematological diseases, submitted to BMT during the ablative treatment with busulfan. This drug is primarily eliminated by conjugation with glutathione, which is catalyzed by glutathione S-transferase (GST) A1-1, a major GST isoform in the liver and kidney. This cytostatic agent was the most seriously toxic to the liver, lungs and nervous system. Hyperuricemia or uric acid nephropathy occurs during initial treatment of patients with leukemia. In bone marrow transplant patients, the dose of busulfan that is given in combination with other drugs can also cause nephrotoxicity prior to transplantation [15, 23, 25].

The population of healthy volunteers was used as the reference for comparison with the clinical material. In healthy persons (females and males jointly), α1-M concentrations and NAG activity in urine did not differ from the values reported in the literature by other authors [1, 9, 11–13, 19, 29].

Available literature lacks sufficient data concerning the changes in the above-mentioned early indicators of renal tubular damage in patients during busulfan-based conditioning therapy. Among these two parameters, especially α1-M concentrations in urine differed statistically significantly in patients in comparison to the control group of healthy persons. Changes in the urinary NAG activity were not so significant as α1-M but after 9th and 13th dose of busulfan its activity has slowly increased.

The obtained results are similar to those reported by other authors, who observed increased protein concentration and enzyme activity in patients with leukemia, myelodysplastic syndromes, solid tumors [12, 28, 30]. Severini et al. reported an increased serum NAG activity in patients with breast, stomach and liver cancers. It can probably be accompanied by increased activity of the enzyme in urine [21]. Some authors observed about 54% increase in α1-M concentration and 66% rise in NAG activity in BMT patients. They noted elevation of these parameters by 95% and 98% after the myeloablative therapy [16].

Patzer et al. reported the increased α1-M concentration in 18/40 patients before myeloablative therapy and in 16/40 patients 1 year after BMT, in 13/33 at 2 years in patients receiving busulfan and other anticancer drugs (cyclophosphamide, melphalan, etoposide, thiopeta or antithymocyte globulin). NAG activity in this group of patients was the highest before BMT but after 1 year it fell down significantly and remained stable until 2 years [17].

In the kidney, ultrastructural metabolic and biochemical changes can be most often observed in S3 segment of proximal tubules. A decrease in ATP quantity, increase in intracellular concentration of calcium, as well as activation of phospholipases have been observed in the cells with insufficient amount of oxygen. Those processes can lead to the damage of cell membrane and increase the release of proteins and enzymes, including α1-M, NAG, into the renal tubules. Another cause of the observed enzymuria can be the loss of integrity of cellular membrane in the renal tubules which results from peroxidation of membrane phospholipids through oxygen free radical and the products of their oxidation, occurring at higher amount in the process of oncogenesis. These changes can lead to hemodynamic disorders [5].

On the basis of this study results, it is concluded that impaired tubular function provoked by supportive treatment and chemotherapy with busulfan can be dangerous and might be the cause of failure in therapy. In patients before BMT treated with busulfan, regular determination especially of urinary α1-M concentration can be helpful for the recognition of the patients at high risk of tubular dysfunction. Disturbances of kidney function should be considered during the planning of individual drug dosage regimens.

References: